(Q86489714)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Dual RAAS blockade has dual effects on outcome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Hiddo J Lambers Heerspink

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Dick de Zeeuw

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

26 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

261-263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2013.65

27 February 2020

exact match

0 references

cites work

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

Prediction of Coronary Heart Disease Using Risk Factor Categories

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.65

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2013.65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529045%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference